- Home
- XTLB vs BLRX Comparison
XTLB vs BLRX Comparison
Compare XTLB & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XTLB
- BLRX
- Stock Information
- Founded
- XTLB 1993
- BLRX 2003
- Country
- XTLB Israel
- BLRX Israel
- Employees
- XTLB N/A
- BLRX N/A
- Industry
- XTLB Biotechnology: Pharmaceutical Preparations
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- XTLB Health Care
- BLRX Health Care
- Exchange
- XTLB Nasdaq
- BLRX Nasdaq
- Market Cap
- XTLB 16.3M
- BLRX 17.3M
- IPO Year
- XTLB 2005
- BLRX 2011
- Fundamental
- Price
- XTLB $1.85
- BLRX $0.11
- Analyst Decision
- XTLB
- BLRX Strong Buy
- Analyst Count
- XTLB 0
- BLRX 2
- Target Price
- XTLB N/A
- BLRX $5.50
- AVG Volume (30 Days)
- XTLB 13.9K
- BLRX 19.4M
- Earning Date
- XTLB 02-21-2025
- BLRX 11-25-2024
- Dividend Yield
- XTLB N/A
- BLRX N/A
- EPS Growth
- XTLB N/A
- BLRX N/A
- EPS
- XTLB N/A
- BLRX N/A
- Revenue
- XTLB $46,000.00
- BLRX $21,991,000.00
- Revenue This Year
- XTLB N/A
- BLRX N/A
- Revenue Next Year
- XTLB N/A
- BLRX N/A
- P/E Ratio
- XTLB N/A
- BLRX N/A
- Revenue Growth
- XTLB N/A
- BLRX N/A
- 52 Week Low
- XTLB $0.77
- BLRX $0.08
- 52 Week High
- XTLB $4.99
- BLRX $1.44
- Technical
- Relative Strength Index (RSI)
- XTLB 50.05
- BLRX 32.10
- Support Level
- XTLB $1.66
- BLRX $0.08
- Resistance Level
- XTLB $1.85
- BLRX $0.14
- Average True Range (ATR)
- XTLB 0.22
- BLRX 0.03
- MACD
- XTLB -0.02
- BLRX -0.00
- Stochastic Oscillator
- XTLB 45.83
- BLRX 10.83
About XTLB XTL Biopharmaceuticals Ltd.
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.